The mortality/survival rates are interesting.
The 90 day primary endpoint mortality results were:
"decreased mortality rate (0% vs 30% in controls) "
The 12 month follow up showed:
"similar survival rates to controls." This is the only 12 month result published where an improvement was not shown over the control group.
Should the product see the commercial light of day, would this point to on-going doses being required over time? If so, it would be great commercially, but a pain in the proverbial for patients. Or, would larger initial dosages do the job? The later stage trials will tell us hopefully.
Does anyone who has experience in the field have any views on this?
Ann: Circulation Publishes Improved Outcomes with Mesoblast Cells, page-12
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.38 |
Change
-0.080(5.50%) |
Mkt cap ! $1.569B | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.43 | $1.37 | $5.321M | 3.829M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 12214 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.38 | 37660 | 5 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |